Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.03|
|52 Week High||AU$0.024|
|52 Week Low||AU$0.053|
|1 Month Change||0%|
|3 Month Change||-9.09%|
|1 Year Change||-23.08%|
|3 Year Change||-31.82%|
|5 Year Change||-55.88%|
|Change since IPO||-97.06%|
Recent News & Updates
|ATH||AU Biotechs||AU Market|
Return vs Industry: ATH underperformed the Australian Biotechs industry which returned 1.7% over the past year.
Return vs Market: ATH underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: ATH is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: ATH's weekly volatility has decreased from 13% to 8% over the past year.
About the Company
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer’s disease, Huntington disease, Parkinson’s disease, and other neurological disorders in Australia. The company’s lead drug candidate is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson’s disease. It is also developing PBT2 that has completed Phase IIa clinical trial to treat Alzheimer’s disease.
Alterity Therapeutics Fundamentals Summary
|ATH fundamental statistics|
Is ATH overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ATH income statement (TTM)|
|Cost of Revenue||AU$360.03k|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.0064|
|Net Profit Margin||-352.78%|
How did ATH perform over the long term?See historical performance and comparison
Is Alterity Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ATH's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ATH's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ATH is unprofitable, so we can't compare its PE Ratio to the Global Biotechs industry average.
PE vs Market: ATH is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ATH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ATH is good value based on its PB Ratio (2.4x) compared to the AU Biotechs industry average (4.8x).
How is Alterity Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: Insufficient data to determine if ATH's forecast earnings growth is above the savings rate (1.9%).
Earnings vs Market: Insufficient data to determine if ATH's earnings are forecast to grow faster than the Australian market
High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: Insufficient data to determine if ATH's revenue is forecast to grow faster than the Australian market.
High Growth Revenue: Insufficient data to determine if ATH's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ATH's Return on Equity is forecast to be high in 3 years time
How has Alterity Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ATH is currently unprofitable.
Growing Profit Margin: ATH is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ATH is unprofitable, and losses have increased over the past 5 years at a rate of 17.4% per year.
Accelerating Growth: Unable to compare ATH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ATH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (46.5%).
Return on Equity
High ROE: ATH has a negative Return on Equity (-50.24%), as it is currently unprofitable.
How is Alterity Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: ATH's short term assets (A$33.5M) exceed its short term liabilities (A$3.1M).
Long Term Liabilities: ATH's short term assets (A$33.5M) exceed its long term liabilities (A$47.7K).
Debt to Equity History and Analysis
Debt Level: ATH is debt free.
Reducing Debt: ATH has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ATH has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ATH has sufficient cash runway for 1.5 years if free cash flow continues to reduce at historical rates of 13.9% each year.
What is Alterity Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ATH's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ATH's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ATH's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ATH's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ATH's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
David Stamler (60 yo)
Dr. David A. Stamler, M.D., serves as Chief Executive Officer at Alterity Therapeutics Limited since January 07, 2021. Dr. Stamler had been the Chief Medical Officer and Senior Vice President of Clinical D...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD731.89K) is above average for companies of similar size in the Australian market ($USD302.06K).
Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.
Experienced Management: ATH's management team is seasoned and experienced (8.3 years average tenure).
Experienced Board: ATH's board of directors are seasoned and experienced ( 14.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 121.8%.
Alterity Therapeutics Limited's employee growth, exchange listings and data sources
- Name: Alterity Therapeutics Limited
- Ticker: ATH
- Exchange: ASX
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$72.206m
- Shares outstanding: 2.41b
- Website: https://alteritytherapeutics.com
Number of Employees
- Alterity Therapeutics Limited
- 460 Bourke Street
- Level 3
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/20 15:17|
|End of Day Share Price||2021/10/20 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.